Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BCL-2: found bound and drugged!

Anthony Letai1

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 530 B, 44 Binney Street, Boston, MA 02115, USA. anthony_letai@dfci.harvard.edu

Trends in Molecular Medicine
|September 10, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

What does BCL-2 do? From new molecular insights to the clinical implications.

Cell death and differentiation·2026
Same author

Drug-tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms.

Cell death and differentiation·2025
Same author

Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML.

Blood advances·2025
Same author

Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia.

bioRxiv : the preprint server for biology·2025
Same author

<i>TP53</i> mutations drive therapy resistance via post-mitochondrial caspase blockade.

bioRxiv : the preprint server for biology·2025
Same journal

Clonal hematopoiesis in Alzheimer's brain: Protective, pathogenic, and context-dependent?

Trends in molecular medicine·2026
Same journal

Targeting amino acid metabolism in hepatocellular carcinoma.

Trends in molecular medicine·2026
Same journal

Turning perfusion into repair through ferroptosis blockade.

Trends in molecular medicine·2026
Same journal

CaMKK2: A tumor stress-integration node.

Trends in molecular medicine·2026
Same journal

Precision gene editing: From proof-of-concept to curative therapies.

Trends in molecular medicine·2026
Same journal

Targeting ferroptosis halts graft deterioration in transplantation.

Trends in molecular medicine·2026
See all related articles

Researchers developed a small-molecule antagonist targeting the BCL-2 protein, which inhibits apoptosis. This new drug effectively kills cancer cells in preclinical models and human cell cultures, offering a promising cancer treatment strategy.

Area of Science:

  • Molecular Biology
  • Oncology
  • Drug Development

Background:

  • The BCL-2 gene, identified in 1985 from the t(14;18) translocation in follicular lymphomas, plays a key role in preventing programmed cell death (apoptosis).
  • Dysregulation of BCL-2 contributes to cancer cell survival by inhibiting apoptosis.

Purpose of the Study:

  • To develop and validate a small-molecule antagonist with high affinity for BCL-2.
  • To assess the efficacy of this antagonist in eliminating cancer cells.

Main Methods:

  • Cloning of the BCL-2 gene.
  • Development of a small-molecule antagonist targeting BCL-2.
  • In vitro testing on primary human cancer cells.
  • In vivo testing using mouse xenograft models.

Related Experiment Videos

Main Results:

  • A high-affinity, mechanistically validated small-molecule antagonist of BCL-2 was successfully developed.
  • The antagonist demonstrated efficacy in killing cancer cells in both mouse xenograft models and in vitro human cancer cell cultures.
  • This achievement highlights a significant advancement in rational drug development over two decades.

Conclusions:

  • The developed small-molecule BCL-2 antagonist shows significant potential for cancer therapy.
  • Targeting antiapoptotic proteins like BCL-2 offers a promising strategy for selectively inducing cancer cell death.
  • Further investigation into BCL-2 antagonists could lead to novel cancer treatments.